SCIENTIFIC ADVISORY BOARD

Prof Ranga Krishnan MB ChB is the Dean of Rush Medical College and Senior Vice President of Rush University Medical Center. From 2009 to 2015, he was Dean at Duke-NUS Graduate Medical School Singapore. Before, he was Professor and the Chairman of the Department of Psychiatry and Behavioural Sciences at Duke University Medical Center for eleven years. Dr Krishnan serves as a member of the board of directors of Singapore Health Services, and is the chairman of the National Medical Research Council Singapore.  He has received numerous awards from various international scientific bodies. He has over authored more than 400 peer reviewed papers, and has written two books on innovative approaches to medical education. He is a member of several professional societies, including the American Psychiatric Association, the American Association for the Advancement of Science, the New York Academy of Sciences, and the National Academy of Medicine.

Dr. Ravi Anand, M.D. Chief Medical Officer, Newron Pharmaceuticals. For over 20 years, Dr. Anand has worked in international drug development and registration departments of major pharmaceutical companies, including F. Hoffmann-La Roche (Switzerland), Sandoz/Novartis (United States) and Organon (Netherlands). Overall, he has been responsible for the conduct of clinical trials in over 30 countries. He has been involved in over 30 investigational new drug applications, and over 7 international new drug applications. He has published extensively, including over 50 papers and 200 abstracts, posters and presentations.

Dr. Atul Pande, M.D. serves as a member of the board of Axovant Sciences (NASDAQ: AXON) since March 2015. He also serves as Chief Medical Advisor of PureTech Health, and President of Verity BioConsulting, a drug development consulting firm. Formerly, he was Chief Medical Officer of Tal Medical, a clinical-stage medical device company. From 2007 to April 2014, Dr. Pande was Senior Vice President Neurosciences and Senior Advisor, Pharmaceutical R&D, at GlaxoSmithKline. He has held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. Dr. Pande is currently a non-executive board member of Autifony Therapeutics and  Karuna Pharmaceuticals.